Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 269

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 269
---
, the Company’s accumulated deficit was $46,947. The Company
has funded its operations to date primarily through equity financing, loans and the issuance of convertible notes. Management expects
that the Company will continue to generate losses from the development, clinical trials, regulatory activities of its product and from
the general administration of its business, which will result in negative cash flow from operating activity.

<div align='center'>F-22</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 1:- | GENERAL (Cont.) |

Additional funding will be required to
complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization
efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.

While the Company has been successful
in raising financing in the past, it is not probable that the Company will be able to successfully obtain additional financing on a timely
basis on terms acceptable to the Company, or will provide the Company with sufficient funds to meet its objective.

Such conditions and other raise substantial
doubts about the Company’s ability to continue as a going concern. Management’s plans include, but are not limited to initial
public offering (the “IPO”) in the US.

In addition, in the event the Company
is unable to have its convertible notes converted as planned or their repayment date deferred, the Company will not have sufficient cash
flows and liquidity to finance its business operations as currently contemplated. If such sufficient financing or payment deferral is
not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity,
cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might
result from the outcome of this uncertainty.

| d. | Impact of the “Iron Swords” War on Israel |

In October 2023, Hamas terrorists infiltrated
Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack,
Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations
in parallel to their continued rocket and terror attacks. In addition, Hezbollah have attacked military and civilian targets in Northern
Israel, to which Israel has responded, including through increased air and ground operations in Lebanon. Since the war broke